PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues

MLA

Nick Beije, et al. PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. Apr. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c5263da951d4750ba26a90d423fb3332&authtype=sso&custid=ns315887.

APA

Nick Beije, Wassim Abida, Emmanuel S. Antonarakis, Elena Castro, Ronald de Wit, Karim Fizazi, Silke Gillessen, Maha Hussain, Joaquin Mateo, Michael J. Morris, David Olmos, Oliver Sartor, Adam Sharp, Christopher J. Sweeney, & Johann S. de Bono. (2023). PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

Chicago

Nick Beije, Wassim Abida, Emmanuel S. Antonarakis, Elena Castro, Ronald de Wit, Karim Fizazi, Silke Gillessen, et al. 2023. “PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues,” April. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c5263da951d4750ba26a90d423fb3332&authtype=sso&custid=ns315887.